Hemodialysis access graft failure Aspirin,
Conditions
Interventions
Group 3 received placebo daily (n=20) ,Group 2 received 80 mg aspirin plus 75 mg dipyridamole daily (n=20),Group 1 who were received 80 mg aspirin daily (n=20)
Prescribe placebo daily,Prescribe 80 mg aspirin plus 75 mg dipyridamole daily ,Prescribe 80 mg aspirin daily
Sponsors
Dr Hasan Ravari
Dr Pouya Tayebi
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: ESRD patients who underwent placement of a new brachial arteriovenous graft have been included.
Exclusion criteria
Exclusion criteria: The exclusion criteria was patient younger than 18 years old, pregnancy and all comorbidities that the use of antiplatelet medication was contraindicated
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary patency time 2 weeks after access creation and evrey 1 month Periodic dialysis access physical examination and well done dialysis | — |
Secondary
| Measure | Time frame |
|---|---|
| Presence of a palpable thrill in created access 2 weeks after access creation and evrey 1 month Periodic dialysis access physical examination | — |
Countries
Iran
Contacts
Public ContactHasan Ravari
Mashhad University of Medical Sciences
Outcome results
None listed